The global regulatory case for aluminium adjuvant safety traces to a pharmacokinetic model built on one study of 2 rabbits per adjuvant type, observed for 28 days, with lost bone samples and one lost brain. The three brains they did measure all contained aluminium. That study has never been replicated.